Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report

Overview of attention for article published in OncoTargets and therapy, July 2016

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 46 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.

Article in American Journal of Cancer Research (October 2021)

Assessment of significant procedures in multigene molecular detection for breast cancer in clinical laboratories: from variant detection to targeted therapy

Article in Breast Cancer (August 2019)

Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study

Article in Cancer Medicine (August 2019)